Inside MEDS: The 2.03M Float and Helomics Deal Behind a +1,397% Run (Forensic Filing Analysis)

TLDR

• MEDS ran +1,397% for the full move ($0.82 on Aug 31 to $12.31 on Sept 16) and +407.1% close-to-close this week ($0.91 to $4.60, Sept 11 to Sept 17) after the Helomics AI cancer-diagnostics acquisition (Sept 15) and a litigation settlement that extinguished ~$19 million in liabilities and retired 364,099 common shares (Sept 18). The tradeable float is just 2,030,000 shares.
• Market cap sits at $3,000,000 with an enterprise value of $25,000,000 — the gap between the two is the debt and convertible structure sitting on top of a tiny common base.
• Cash position is $10,600,000 against a quarterly burn of $-3,410,000, for 9.4 months of runway. That is not an imminent cash crunch, but it is the clock every dilution facility on file is counting against.
• The priming filings were public before the vertical candle: an S-1 (August 7), a preliminary Schedule 14C information statement (August 31), and a run of seven 8-K filings across the window. A reader of the filings had the setup in hand before the Sept 15 gap.
• The trade math: a $10,000 position entered at the Sept 11 close of $0.91 and held to Wednesday's $4.60 close returned $50,710 (+407.1%). The Sept 16 regular session alone ran +50.2% from a $4.04 open to a $6.06 close.

The Anatomy of a 2.03M-Share Float Squeeze

MEDS is a textbook supply-constrained move: a 2,030,000-share float, a catalyst that forced buyers into a market with almost no shares to sell, and a volume expansion from roughly 72,000 shares a day to 188,572,504 shares in a single session. On September 16, MEDS traded 92.9 times its entire float. When that much demand hits that few shares, price is the only variable left to move — and it moved from a $0.82 base on August 31 to a $12.31 session high on September 16, a +1,397% full move.

The forensic point is that none of this required a crystal ball. The filings and the news wire described the structure in advance. DataMeds AI, Inc. is a Wholesale-Non-Durable name on Nasdaq — the exact sector that rotated in hard this week, with average RVOL climbing from 0.58 to 4.82 (+737%). Sector rotation plus a micro float plus a fresh catalyst is the three-part signature this desk has documented before in the DAIC filing forensic breakdown and the IPST short-squeeze forensic. MEDS is the same pattern, a different ticker.

What the Filings Signaled Before the Candle

MEDS filed 15 SEC filings in the last 90 days, and the sequence — not any single document — is the tell. The S-1 registration statement (August 7) put a registered share block on file. The preliminary Schedule 14C information statement (August 31) signals a corporate action being pushed through by written consent rather than a shareholder vote, which for a controlled micro-float name is how structure changes get made quickly. The seven 8-K filings — dated September 17, September 16, August 18, August 14, August 4, and July 28, among others — are the event stream: each one is a material event the company was legally required to disclose in real time.

Here is the filing timeline, with what each form means and the specific structural consequence:

Notice the clustering: the NT 10-Q and 10-Q around August 14–17, the Schedule 14C on August 31, then two 8-K filings bracketing the biggest volume day of the entire move. This is not a company gone quiet. It is a company generating disclosure events at the exact moment its float is being repriced.

Share Structure Impact: 2.03M Float Against 5.28M PIPE Warrants

The dilution structure is where the risk lives, and MEDS carries five active facilities plus two completed, historical raises. The active facilities are the forward-looking overhang; the completed ones already happened and are not a current threat.

Active (currently exercisable or drawable):

• September 2025 Warrant — strike $35.00, 77,200 warrants, agent HC Wainwright. Deeply out of the money against a stock that closed Wednesday at $4.60.
• May 2026 PIPE Warrant — strike $7.50, 5,280,000 warrants. This is the one that matters. At 5.28M warrants against a 2.03M float, exercise more than triples the tradeable share count — but only if the stock trades above $7.50. MEDS printed a $12.31 session high on September 16, which put these in the money intraday.
• May 2026 Convertible Note — conversion price $6.00, remaining principal $21,132,812. Convertible into common at $6.00, which the stock cleared on the September 16 spike.
• April 2025 Hudson Global SPA — an equity line with $50,000,000 remaining capacity. This is a draw-down financing tool the company can tap into open-market strength.
• April 2026 Shelf — $2,424,148 remaining, with a baby-shelf restriction: the price must exceed $36.92 to use full capacity. That threshold sits far above the current price, which constrains how much of the shelf is usable today.

Completed / historical (already raised — not active overhang):

• January 2026 Convertible Note — fully converted, $0 remaining. The dilution already occurred; this is not a current threat.
• July 2025 S-1 Offering — status Priced, raised $5,000,000 across 7,142,862 shares. A closed historical raise.

The structural reality: a 2.03M float is the accelerant, but the 5.28M PIPE warrants at $7.50 and the $21.1M convertible note at $6.00 are the ceiling. Every push above those strikes hands holders a reason to convert and sell into strength. That is the two-sided nature of every dilution setup — the same mechanics that constrain supply on the way up create supply on the way down.

Price Action Context: The Session-by-Session Read

The move built over three sessions of escalating volume, and the OHLC tells the whole story. Here is the regular-session and full-day data straight off the tape:

The September 14 session traded 46,241 shares — a dead tape. The very next day volume exploded to 65,020,038 as the stock closed +82.1% ($0.89 open to $1.63 close), with the after-hours session pushing to a $1.91 close. That overnight gap set up September 16: a $1.71 pre-market open ramping to a $4.04 regular open, a $6.06 regular close (+50.2%), and a $6.21 after-hours close on 188,572,504 shares. The full-day high of $12.31 is where the +1,397% full-move headline comes from — a session high, not the close.

Then September 17 delivered the give-back: a $6.73 open, a $4.60 close, -31.6% on the day and only 7,071,667 shares. That volume collapse — from 188.6M to 7.1M — is the exhaustion signature. When the supply/demand imbalance resolves and volume dries up, the vertical part of the move is over. MEDS is the same arc documented in the WCT offering-and-reverse-split forensic: spike, distribution, give-back.

MEDS's 188,572,504-share day also fits a pattern the scanner has been logging all week. In the past 30 days, 129 high-volume breakout setups (100M+ shares traded intraday) triggered and all 129 hit their target — 100% follow-through, with 38 firing this week against a ~27 weekly average. Separately, 161 intraday-doubling setups fired and all 161 reached completion. MEDS is one data point inside a broad, high-velocity tape.

The Opportunity: Where the Money Was and Where the Risk Sits

The tradeable window on MEDS was enormous, and so is the risk on the other side. Using a $10,000 base: a position entered at the September 11 close of $0.91 and held to Wednesday's $4.60 close returned $50,710 (+407.1%). The single cleanest day-trade was September 16's regular session — a $4.04 open to a $6.06 close captured +50.2%, or $15,020 on the day, without touching the overnight risk. The September 15 regular session added +82.1% ($0.89 open to $1.63 close) for the trader who caught the first volume expansion.

The pre-offering run is the opportunity; the active facilities are the risk. Both are visible in the same filings.

On the risk side: the May 2026 PIPE warrants (5,280,000 at $7.50) and the $21,132,812 convertible note at $6.00 are the overhang. Every close above $6.00–$7.50 arms a holder to convert and sell. The Hudson Global equity line with $50,000,000 remaining is a draw-down tool the company can use into open-market strength. And the cash math frames the urgency without any guesswork: $10,600,000 on hand, a $-3,410,000 quarterly burn, 9.4 months of runway. That is not a distressed balance sheet, but it is the reason financing facilities exist on the shelf.

The opportunity side is the mechanical squeeze itself. A 2.03M float with short interest at 8.1% and a fresh catalyst — the Helomics AI cancer-diagnostics acquisition (September 15) and the September 18 settlement that extinguished ~$19 million in liabilities and retired 364,099 common shares — is the exact supply-demand imbalance that produces vertical candles. Fast traders who recognized the float-plus-catalyst combination rode the September 15–16 expansion; slower ones bought the September 17 give-back.

How You Could Have Caught This Before It Ran

The pre-signal was a combination of float, filings, and sector rotation — all filterable before September 15. Three triggers preceded the vertical move:

1. Float under 5M. MEDS's 2,030,000-share float puts it in the smallest float bucket. Squeezes concentrate in names where supply is thin. A scanner sorted by float ascending surfaces these before the catalyst hits.
2. The filing cadence. The S-1 (August 7) and the Schedule 14C (August 31) were public weeks before the run. A name generating registration and corporate-action filings on a micro float is building toward a structural event.
3. Sector rotation. Wholesale-Non-Durable RVOL surged from 0.58 to 4.82 (+737%) week-over-week. Capital rotated into the exact sector MEDS trades in.

How to Find These Setups on SNACS

The fastest path is the SEC research tool plus the scanner working together. Start in SEC research: the Dilution Snapshot surfaces active facility counts, shares at risk, and lowest exercise price for any ticker — for MEDS that means the five active facilities, the 5.28M PIPE warrants at $7.50, and the $6.00 convertible instantly, without reading a single filing by hand. The Filing Browser lets you pull the S-1 and the Schedule 14C in an inline SEC Filings viewer. Ask the AI Chat a plain-English question — "which sub-$1 Nasdaq names under 5M float have an active S-1 and a recent 8-K cluster" — and it reads the filing corpus for you.

Then build the scanner filter: price range $0.50–$20, float under 5M, RVOL 5x minimum, sort by RVOL descending. Click any matching ticker to open its ticker details page — chart, dilution risk panel, recent news, and SEC filings, all without leaving the scanner. Save that filter as a named preset, then link it to a Dynamic Watchlist so matches auto-populate in real time; matched tickers show a colored square in the main stream. The moment a Wholesale-Non-Durable micro-float name lights up on volume, you see it.

For the pattern itself, the Playbook builder lets you encode the setup — historical context (thin float, active S-1), trigger (volume expansion past 50x float), entry, and exit — and its live matching drops a star indicator on any scanner ticker that fits. When you are done, log the fills in your trading journal: the AI Insights break down your MFE capture rate and best time-of-day so you learn where you left money on the table. For a deeper walkthrough of the mechanics, the INDP filing forensic covers the shelf-and-ATM version of this same read.

The Broader Tape: A Risk-Off Backdrop That Still Produced Runners

The macro call this week is Risk-Off / Consolidation, and that context matters for position sizing. The Russell 2000 (IWM) closed at $285.43, down -6.5% from its 52-week high of $305.18 and -5.4% over 20 days — small caps are the weakest major proxy. The S&P 500 (SPY) closed at $762.60, within 5% of its 52-week high, up +0.6% over five days. The Nasdaq 100 (QQQ) closed at $716.92, and the Dow Jones Industrial (DIA) at $518.35, down -3.0% over 20 days. A defensive backdrop means small-cap setups fail more often — tighten stops and reduce size until breadth recovers.

Even so, the tape stayed runner-heavy: 27 names ran +50% or more this week, with 8 over +100% and 4 over +200%, against a four-week baseline of about 5.5 runners over +50%. MEDS led that list at +407.1%, followed by AEMD (+329.9%, post-split rebase), PAAI (+224.3%), VEEA (+224.0%, post-split rebase), and PDSB (+162.6%). Wholesale-Non-Durable was the rotation MEDS rode; the MEDS +588% weekly rotation read covers how utilities and energy led the same tape.

On the market-wide dilution picture — approximate counts; exact totals withheld — there are ~6,000 active warrant facilities, ~3,200 active shelves, ~2,100 active ATM programs, ~1,500 active convertible notes, and ~500 active equity lines across the small-cap universe. In the past 3 days, 13 companies filed 424B5 pricing supplements, 4 fresh S-3 shelf registrations landed, and 277 8-K filings hit across 251 unique tickers. That is the raw filing flow a forensic trader screens every morning for the next MEDS.

Conclusion: What to Watch Next

MEDS's forward risk is the give-back and the overhang, not another leg up on the same fuel. Volume collapsed from 188,572,504 shares to 7,071,667 on September 17 as the stock fell -31.6% — the vertical move is spent. The watch items now are the active facilities: any close back above $6.00 arms the convertible note, and above $7.50 arms the 5.28M PIPE warrants, both of which create supply. With 9.4 months of runway and a $50,000,000 equity line available, watch for the company to use open-market strength. For the next setup, screen for the same signature — sub-5M float, active S-1, sector rotation, and the first day volume jumps from thousands to tens of millions. That combination is what preceded this one.

FAQ

What caused MEDS stock to run +1,397%?

MEDS ran +1,397% ($0.82 on August 31 to a $12.31 session high on September 16) on a supply-demand squeeze: a 2,030,000-share float met a fresh catalyst — the September 15 Helomics AI cancer-diagnostics acquisition — and volume expanded from roughly 72,000 shares a day to 188,572,504 shares on September 16. With that few shares available, price was the only variable that could absorb the demand.

What is MEDS's float and why does it matter?

MEDS's tradeable float is 2,030,000 shares, one of the smallest float buckets on the tape. A tiny float means a catalyst forces buyers into a market with almost no shares to sell, which is the mechanical accelerant behind every micro-float squeeze. On September 16, MEDS traded 92.9 times its entire float in a single session.

Is MEDS at risk of dilution?

MEDS carries five active dilution facilities: 77,200 warrants at a $35.00 strike, 5,280,000 PIPE warrants at $7.50, a $21,132,812 convertible note at $6.00, a $50,000,000 equity line, and an April 2026 shelf with $2,424,148 remaining under a $36.92 baby-shelf threshold. With $10,600,000 cash against a $-3,410,000 quarterly burn (9.4 months runway), the facilities are real overhang, though not an imminent cash crunch. Two prior raises — a fully-converted January 2026 note and a priced July 2025 S-1 — are historical, not current threats.

What does a 424B5 filing mean for a stock?

A 424B5 is a pricing supplement filed under an existing shelf registration — it means an offering is live and shares are being priced for sale. In the past 3 days, 13 companies filed 424B5 pricing supplements across the small-cap universe. When a 424B5 hits, dilution is happening now, which is different from an S-3 shelf (capacity registered for future use) or an S-1 (a fresh registration statement).

How much could a trader have made on MEDS?

Using a $10,000 base, a position entered at the September 11 close of $0.91 and held to Wednesday's $4.60 close returned $50,710 (+407.1%). The single cleanest day-trade was the September 16 regular session, which ran +50.2% from a $4.04 open to a $6.06 close — $15,020 on the day without carrying overnight risk. The September 15 regular session added +82.1% ($0.89 to $1.63).

How do I find micro-float squeeze setups before they run?

In the SNACS scanner, set price $0.50–$20, float under 5M, RVOL 5x minimum, and sort by RVOL descending. Cross-reference the SEC research Dilution Snapshot for active facilities and the Filing Browser for a recent S-1 or 8-K cluster. Save the filter as a preset and link it to a Dynamic Watchlist so matches auto-populate in real time.

Why did MEDS drop -31.6% on September 17?

MEDS fell -31.6% on September 17 (a $6.73 open to a $4.60 close) as volume collapsed from 188,572,504 shares to 7,071,667 — the exhaustion signature. When the supply-demand imbalance that drives a vertical move resolves and volume dries up, the spike distributes and gives back. Active facilities near the $6.00 convertible price and $7.50 warrant strike also create selling pressure on pushes above those levels.

What sector was MEDS in and did the sector matter?

MEDS is a Wholesale-Non-Durable name, and the sector rotated in hard this week — average RVOL climbed from 0.58 to 4.82 (+737%) week-over-week. Sector rotation is one of the three-part signatures behind these moves: a thin float, a fresh catalyst, and capital rotating into the exact sector the stock trades in.